Moderna’s COVID-19 vaccine candidate has moved past the first part of the United States approval process, with reviewers from a Food & Drug Administration (FDA) panel stating that it shows high effectiveness in protecting against the disease without major safety concerns. The FDA meets later this week to consider approving the vaccine, and while not legally bound by the guidance of the review panel, it does often follow its guidance.